[HAPSENG] YoY Annualized Quarter Result on 30-Jun-2008 [#2]

Stock
[HAPSENG] HAP SENG CONSOLIDATED BHD
Announcement Date
26-Aug-2008
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2008
Quarter
30-Jun-2008 [#2]
Profit Trend
QoQ- 67.36%
YoY- 191.49%
Quarter Report
Latest QR
Upcoming QR
HAPSENG's Result
HAPSENG's Financial Summary
View:
Show?
Annualized Quarter Result
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
Revenue 3,419,736 2,503,394 2,277,218 2,679,766 2,085,542 1,742,946 1,433,022 15.83%
PBT 632,234 486,886 172,356 625,816 212,524 110,784 111,084 34.15%
Tax -162,148 -68,874 -28,064 -156,126 -56,434 -32,842 -34,648 29.79%
NP 470,086 418,012 144,292 469,690 156,090 77,942 76,436 35.92%
-
NP to SH 345,414 344,312 107,960 415,628 142,588 68,810 67,370 31.81%
-
Tax Rate 25.65% 14.15% 16.28% 24.95% 26.55% 29.65% 31.19% -
Total Cost 2,949,650 2,085,382 2,132,926 2,210,076 1,929,452 1,665,004 1,356,586 14.02%
-
Net Worth 8,699,999 2,468,226 2,327,112 2,203,234 1,557,733 1,472,816 1,415,094 35.91%
Dividend
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
Div 144,076 67,622 56,346 56,348 40,839 41,238 41,273 23.52%
Div Payout % 41.71% 19.64% 52.19% 13.56% 28.64% 59.93% 61.26% -
Equity
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
Net Worth 8,699,999 2,468,226 2,327,112 2,203,234 1,557,733 1,472,816 1,415,094 35.91%
NOSH 1,847,133 563,522 563,465 563,486 583,420 589,126 589,622 21.28%
Ratio Analysis
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
NP Margin 13.75% 16.70% 6.34% 17.53% 7.48% 4.47% 5.33% -
ROE 3.97% 13.95% 4.64% 18.86% 9.15% 4.67% 4.76% -
Per Share
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
RPS 185.14 444.24 404.15 475.57 357.47 295.85 243.04 -4.49%
EPS 18.70 61.10 19.16 73.76 24.44 11.68 11.42 8.69%
DPS 7.80 12.00 10.00 10.00 7.00 7.00 7.00 1.84%
NAPS 4.71 4.38 4.13 3.91 2.67 2.50 2.40 12.06%
Adjusted Per Share Value based on latest NOSH - 563,530
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
RPS 137.36 100.55 91.47 107.63 83.77 70.01 57.56 15.83%
EPS 13.87 13.83 4.34 16.69 5.73 2.76 2.71 31.77%
DPS 5.79 2.72 2.26 2.26 1.64 1.66 1.66 23.50%
NAPS 3.4944 0.9914 0.9347 0.8849 0.6257 0.5916 0.5684 35.91%
Price Multiplier on Financial Quarter End Date
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
Date 30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 29/07/05 -
Price 1.75 0.96 0.83 0.92 1.09 0.72 0.71 -
P/RPS 0.95 0.22 0.21 0.19 0.30 0.24 0.29 22.20%
P/EPS 9.36 1.57 4.33 1.25 4.46 6.16 6.21 7.17%
EY 10.69 63.65 23.08 80.17 22.42 16.22 16.09 -6.67%
DY 4.46 12.50 12.05 10.87 6.42 9.72 9.86 -12.54%
P/NAPS 0.37 0.22 0.20 0.24 0.41 0.29 0.30 3.60%
Price Multiplier on Announcement Date
30/06/11 30/06/10 30/06/09 30/06/08 31/07/07 31/07/06 31/07/05 CAGR
Date 24/08/11 25/08/10 26/08/09 26/08/08 27/09/07 27/09/06 27/09/05 -
Price 1.30 0.88 0.85 0.80 1.01 0.68 0.73 -
P/RPS 0.70 0.20 0.21 0.17 0.28 0.23 0.30 15.39%
P/EPS 6.95 1.44 4.44 1.08 4.13 5.82 6.39 1.42%
EY 14.38 69.43 22.54 92.20 24.20 17.18 15.65 -1.41%
DY 6.00 13.64 11.76 12.50 6.93 10.29 9.59 -7.61%
P/NAPS 0.28 0.20 0.21 0.20 0.38 0.27 0.30 -1.15%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment